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Abstract
Background: Porcine reproductive and respiratory syndrome virus (PRRSV) causes major economic losses in the pig 
industry worldwide. In vivo, the virus infects a subpopulation of tissue macrophages. In vitro, PRRSV only replicates in 
primary pig macrophages and African green monkey kidney derived cells, such as Marc-145. The latter is currently used 
for vaccine production. However, since virus entry in Marc-145 cells is different compared to entry in primary 
macrophages, specific epitopes associated with virus entry could potentially alter upon growth on Marc-145 cells. To 
avoid this, we constructed CHO and PK15 cell lines recombinantly expressing the PRRSV receptors involved in virus 
entry into macrophages, sialoadhesin (Sn) and CD163 (CHOSn-CD163 and PK15Sn-CD163) and evaluated their potential for 
production of PRRSV.
Results: Detailed analysis of PRRSV infection revealed that LV and VR-2332 virus particles could attach to and 
internalize into the CHOSn-CD163 and PK15Sn-CD163 cells. Initially, this occurred less efficiently for macrophage grown virus 
than for Marc-145 grown virus. Upon internalization, disassembly of the virus particles was observed. The two cell lines 
could be infected with PRRSV strains LV and VR-2332. However, it was observed that Marc-145 grown virus infected the 
cells more efficiently than macrophage grown virus. If the cells were treated with neuraminidase to remove cis-acting 
sialic acids that hinder the interaction of the virus with Sn, the amount of infected cells with macrophage grown virus 
increased. Comparison of both cell lines showed that the PK15Sn-CD163 cell line gave in general better results than the 
CHOSn-CD163 cell line. Only 2 out of 5 PRRSV strains replicated well in CHOSn-CD163 cells. Furthermore, the virus titer of all 5 
PRRSV strains produced after passaging in PK15Sn-CD163 cells was similar to the virus titer of those strains produced in 
Marc-145 cells. Analysis of the sequence of the structural proteins of original virus and virus grown for 5 passages on 
PK15Sn-CD163 cells showed either no amino acid (aa) changes (VR-2332 and 07V063), one aa (LV), two aa (08V194) or 
three aa (08V204) changes. None of these changes are situated in known neutralizing epitopes.
Conclusions: A PRRSV susceptible cell line was constructed that can grow virus to similar levels compared to currently 
available cell lines. Mutations induced by growth on this cell lines were either absent or minimal and located outside 
known neutralizing epitopes. Together, the results show that this cell line can be used to produce vaccine virus and for 
PRRSV virus isolation.
Background
Porcine reproductive and respiratory syndrome virus
(PRRSV) is a member of the family Arteriviridae, order
Nidovirales [1,2] causing major economic losses in the pig
industry worldwide [3]. PRRSV infection may result in
reproductive failure in sows and is involved in the porcine
respiratory disease complex (PRDC) [4-9].
In vivo, the virus infects a subpopulation of tissue mac-
rophages [10-13]. In vitro, efficient PRRSV replication is
only observed in primary pig macrophages (e.g. alveolar
macrophages) [14], differentiated monocytes [15] or Afri-
can green monkey kidney derived cells, such as Marc-145
[14,16]. Infection of macrophages, the natural host cell of
PRRSV, occurs via a few similar but also different recep-
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tors compared to infection of Marc-145 cells [17]. PRRSV
first attaches to macrophages via heparan sulphate [18],
then the virus is internalized via sialoadhesin (Sn) [19].
CD163 is also involved in infection of macrophages,
probably at the stage of virus disassembly [20]. PRRSV
infection of Marc-145 cells occurs via binding to a hepa-
rin-like molecule as a first step [21]. The nucleocapsid of
PRRSV is described to bind to the intermediate filament
vimentin, which is suggested to mediate transport of the
virus to the cytosol [22]. CD151 may be involved in
fusion of the viral envelope and the endosome, but the
precise mechanism is yet unknown [23]. CD163 is also
essential for PRRSV infection of Marc-145 cells, but its
role in this process is still unclear [24].
Currently, PRRS vaccine virus is produced in Marc-145
cells. However, since virus entry in Marc-145 cells is dif-
ferent compared to entry in primary macrophages [25]
and because adaptation is needed for growth on Marc-
145 cells [26], it is possible that specific epitopes associ-
ated with virus neutralization are lost or modified.
Although virus production in primary macrophages
would be ideal to avoid adaptation, these cells cannot be
used beca use  of  ba t c h va ria t io n, ris k of  c o n ta mi na t ion
with other pathogens present in the macrophages iso-
lated from pigs and high production costs. Previous
results in our lab showed that non-permissive cells tran-
siently transfected with Sn only sustained internalization,
but not infection [19]. Non-permissive cells transiently
transfected with CD163 allow a low level of infection
depending on the cell type used [24]. Co-expression of
both Sn and CD163 is the most efficient for PRRSV infec-
tion in different cell lines evaluated [20].
T o avoid the problems associated with PRRS vaccine
virus production in other cell types, the aim of this study
was to construct cell lines that recombinantly express Sn,
the receptor that mediates PRRSV attachment to and
internalization into macrophages [19,27] and CD163,
which is most probably involved in virus disassembly in
macrophages [20]. Both Sn and CD163 are needed to
make a PRRSV susceptible cell line for virus production
that mimics the natural entry pathway in macrophages.
Methods
Cells, viruses and plasmids
CHO-K1 cells were cultivated in F12 medium and PK15
c e l l s  i n  D u l b e c c o  M o d i f i e d  E a g l e  M e d i u m  ( D - M E M ) .
Both media were supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 1 mM non-essential
amino acids, 1 mM sodium pyruvate and a mixture of
antibiotics. The cells were maintained in a humidified 5%
CO2  atmosphere at 37°C. Macrophages cultivated in
medium containing RPMI-1640, 10% FBS, 2 mM L-glu-
tamine, 1 mM non-essential amino acids, 1 mM sodium
pyruvate and a mixture of antibiotics were used for titra-
tion. A pcDNA3.1D/V5-HisTOPO plasmid containing Sn
cDNA and geneticine resistance gene [19] and a pBUD
plasmid with CD163 cDNA and zeocin resistance gene
were used for transfection. To construct the pBUD plas-
mid containing CD163, CD163 from a pcDNA3.1D/V5-
HisTOPO plasmid containing CD163 [20], was cloned
into a pBUD plasmid via restriction site HindIII and
XbaI. The European prototype PRRSV strain Lelystad
virus (LV), grown on Marc-145 cells and macrophages
[14], the American prototype PRRSV strain VR-2332
grown on Marc-145 cells [26], and three recent Belgian
isolates, belonging to the European type, grown on mac-
rophages (07V063, 08V204 and 08V194) were used for
inoculation.
Transfection and selection
CHO-K1 and PK15 cells were transfected with FuGENE 6
(Roche) or Lipofectamine Plus (Invitrogen, Merelbeke,
Belgium) respectively, according to the manufacturer's
instructions. CHO-K1 and PK15 cells were first trans-
fected with a plasmid containing the Sn cDNA and gene-
ticine resistance gene. The cells were single cell cloned
and selected for Sn expressing CHO and PK15 cells with
geneticine (200 μg/ml, GIBCO). Afterwards, the obtained
CHOSn and PK15Sn cells were transfected with a plasmid
containing the CD163 cDNA and zeocin resistance gene
and single cell cloned. For the selection of CHOSn and
PK15Sn cells expressing CD163, zeocin (200 μg/ml, Invit-
rogen, Merelbeke, Belgium) was used.
Screening of cells expressing Sn and CD163 by 
immunofluorescence staining
Transfected CHO-K1 and PK15 cells were fixed with
methanol and stained with primary monoclonal antibod-
ies (mAb) against Sn (mAb 41D3) [19,28] and CD163
(mAb 2A10, AbD Serotec) [29,30]. As a secondary anti-
body, fluorescein isothiocyanate (FITC)-conjugated goat
polyclonal anti-mouse immunoglobulins (Invitrogen,
Molecular Probes, Merelbeke, Belgium) were used.
Screening of cells expressing Sn and/or CD163 was per-
formed with a fluorescence microscope (Leica Microsys-
tems GmbH, Heidelberg, Germany).
Analysis of PRRSV infection of CHOSn-CD163 and PK15Sn-CD163 
cells by immunoperoxidase staining
CHOSn-CD163 and PK15Sn-CD163 c e l ls  w e r e  s eed ed  i n  9 6 -
well plates and inoculated with virus. At different time
points post inoculation (pi), the cells were fixed with
methanol and an immunoperoxidase staining was per-
formed [18]. Briefly, viral antigen positive cells were
stained with primary mAb anti-nucleocapsid P3/27 [31]
and secondary antibody peroxidase labeled goat anti-
mouse immunoglobulin (Ig) (DakoA/S, Glostrup, Den-
mark). Afterwards, 3-amino-9-ethylcarbazole (AEC) sub-Delrue et al. BMC Biotechnology 2010, 10:48
http://www.biomedcentral.com/1472-6750/10/48
Page 3 of 12
strate (Sigma, Bornem, Belgium) was added. The amount
of infected cells was counted with a light microscope
(Olympus Optical Co., Hamburg, Germany).
Attachment, internalization, disassembly and infection of 
CHOSn-CD163 and PK15Sn-CD163 cells with PRRSV analyzed by 
immunofluorescence staining
To determine attachment, internalization, disassembly
and infection of CHOSn-CD163 and PK15Sn-CD163 cells, the
cells were seeded at 200 000 cells/mL and after 2 days of
cultivation they were inoculated with virus. The cells
were fixed with methanol after 1 hour incubation at 4°C
to investigate attachment, since virus is not able to inter-
nalize at 4°C. The cells were fixed after 1 hour incubation
at 37°C to determine the internalized particles. After 5
hours incubation at 37°C, the cells were fixed to analyze
disassembly (disappearance of staining). To analyze infec-
tion, the cells were fixed after 24 hours incubation at
37°C. The virus was stained with a primary mAb anti-
nucleocapsid P3/27 [31] and a secondary FITC-conju-
gated goat polyclonal anti-mouse immunoglobulins
(Invitrogen, Molecular Probes, Merelbeke, Belgium).
Virus particles were counted on images acquired with a
TCS SP2 laser scanning spectrum confocal system (Leica
Microsystems GmbH, Heidelberg, Germany).
Virus production after passaging in CHOSn-CD163 and PK15Sn-
CD163 cells
CHOSn-CD163 and PK15Sn-CD163 cells were seeded at 200
000 cells/mL in Tissue Culture (TC) flasks. After 2 days of
cultivation, the cells were initially inoculated with 105
TCID50 of each virus strain. After 3 and 5 days post inoc-
ulation (dpi), the supernatant was collected and centri-
fuged for 30 min at 30 × g at 4°C. The supernatant was
stored at -70°C and titrated. Virus titration was per-
formed on 24 hours cultivated alveolar macrophages fol-
lowing the standard procedure [12]. After 3 days of
incubation at 37°C, the occurrence of cytopathic effect
(CPE) was investigated. Macrophages were fixed at 3 dpi
and an immunoperoxidase staining was performed to
identify infected cells. The 50% tissue culture infective
dose (TCID50) was calculated.
Virus sequencing after passaging virus in PK15Sn-CD163 cells
RNA was extracted from PRRSV passaged 4 times on
PK15Sn-CD163 cells using a RNeasy Protect Mini Kit (QIA-
GEN) and reverse transcribed using random hexamers
and MultiScribe Reverse Transcriptase (Applied Biosys-
tems) according to the manufacturer's guidelines.
The primers ORF2a-FW (5'-gtsacaccktatgattacg-3') and
ORF2a-REV (5'-tcatrccctattytgcacca-3'), ORF3-FW (5'-
agcctacagtacaacaccac-3') and ORF3-REV (5'-
agaaaaggcacgcagaaagca-3'), ORF4-FW (5'-cggcccaittcca-
tccigag-3') and ORF4-REV (5'-cattcagctcgcataicgtcaag-
3'), ORF5-FW2 (5'-tgcticatttcitgacacc-3') and ORF5-
REV1 (5'-accttaagigcitatatc-3'), ORF6FW (5'-taccaactttct-
tctggac-3') and ORF6REV (5'-acccagcaactggcacag-3'),
ORF7-FW (5'- tggcccctgcccaicacg-3') and ORF7-REV (5'-
tcgccctaattgaataggtga-3') were used to amplify the differ-
ent ORFs with T aq Polymerase (Invitrogen, Merelbeke,
Belgium). PCR products were treated with Exonuclease I
and Antarctic Phosphatase (New England Biolads, Ips-
wich, USA) and used directly for cycle sequencing with a
Big Dye Terminator Cycle sequencing kit V1.1 (Applied
Biosystems, Foster City, USA) and PRRSV primers. Cycle
sequencing reaction products were purified by ethanol
precipitation and separated on an ABI Genetic 310
(Applied Biosystems, Foster City, USA).
The sequences were analyzed and compiled by BlastN
and BlastP http://www.ncbi.nlm.nih.gov, and Sixframe,
ClustalW, Align (workbench.sdsc.edu). The Genbank
accession number are for 07V063 [Genbank:GU737264],
08V204 [Genbank:GU737266] and for 08V194 [Gen-
bank:GU737265].
Results
Construction of CHOSn-CD163 and PK15Sn-CD163 cell line
CHO-K1 and PK15 cells were transfected with Sn and
CD163 and selected for cells expressing both receptors as
shown in Figure 1A. The presence of Sn and CD163 was
confirmed by immunofluorescence staining (Figure 1B).
16 CHO and 4 PK15 clones co-expressing Sn and CD163
(CHOSn-CD163 and PK15Sn-CD163) were selected. 10 CHO
and 4 PK15 clones were obtained, in which 100% of the
cells retained stable expression of Sn and CD163 for at
least 15 passages. The other 6 CHO clones lost either Sn
or CD163 expression after a few passages. After a prelim-
inary screening for PRRSV susceptibility, 3 CHO clones
(IC5, ID9 and IF3) and 2 PK15 clones (IXH7 and IXA3)
were retained for further analysis.
Effect of cell density and cultivation time of CHOSn-CD163 and 
PK15Sn-CD163 cells on the susceptibility to PRRSV infection
To determine the effect of cell density and cultivation
time of the cells on susceptibility to PRRSV infection, 3
CHOSn-CD163 cell clones (IC5, ID9 and IF3) and 2 PK15Sn-
CD163 cell clones (IXH7 and IXA3) were seeded at differ-
ent cell densities (100 000, 200 000 or 300 000 cells/mL)
and inoculated with 50 μL containing 104 TCID50 Marc-
145 grown LV, Marc-145 grown VR-2332 or macrophage
grown LV at different days post seeding (1, 2 or 3 days
post seeding). After 2 dpi, the cells were fixed and
stained.
For Marc-145 grown virus infection of CHOSn-CD163
cells, little difference was observed between different cell
densities and days post seeding, although a density of 200
000 cells/mL and inoculation at 2 days post seeding
seemed a little more efficient. The VR-2332 strainDelrue et al. BMC Biotechnology 2010, 10:48
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Figure 1 Construction of CHOSn-CD163 and PK15Sn-CD163 cell lines. A) Schematic representation of the construction of CHOSn-CD163 and PK15Sn-
CD163 cell lines
To construct a cell line co-expressing Sn and CD163, CHO-K1 or PK15 cells were transfected with a plasmid containing the Sn cDNA and a geneticine 
resistance gene. The cells were single cell cloned and clones were screened for Sn expressing cells. After selection for geneticine resistance, the ob-
tained CHOSn or PK15Sn cells were transfected with a plasmid containing the CD163 cDNA and a zeocin resistance gene, which allowed selection of 
cells expressing both Sn and CD163.
B) Immunofluorescence staining of the obtained CHOSn-CD163 or PK15Sn-CD163 cells for Sn and CD163.
Some CHOSn-CD163 clones (IF3, IC5 and ID9) and PK15Sn-CD163 clones (IXA3 and IXH7) are represented with their Sn and CD163 expression.Delrue et al. BMC Biotechnology 2010, 10:48
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infected the CHOSn-CD163 cells more efficiently than the
LV strain. For PK15Sn-CD163 cells, the infection rate for
Marc-145 grown LV as well as VR-2332 was approxi-
mately 80%, independently of densities and cultivation
time. CHOSn-CD163 clones IC5, ID9 and IF3 were equally
sensitive to virus infection. There was no difference in
sensitivity for infection between PK15Sn-CD163  clones
IXH7 and IXA3. The PK15Sn-CD163 cells could be infected
more efficiently than the CHOSn-CD163 cells (Figure 2).
Both CHOSn-CD163 and PK15Sn-CD163 cells showed a low
infection rate with macrophage grown virus. The cell
density had no influence on infection. There were no dif-
ferences between clone IC5, ID9 and IF3 for CHOSn-CD163
and between IXH7 and IXA3 for PK15Sn-CD163 cells (Fig-
ure 2). Overall, Marc-145 grown virus strains could infect
the cells more efficiently than macrophage grown virus
strains tested.
Effect of neuraminidase treatment of CHOSn-CD163 and 
PK15Sn-CD163 cells on the susceptibility to macrophage 
grown PRRSV infection
The previous section showed that macrophage grown
PRRSV infection rate is very low. Previously, it was how-
ever shown that infection of macrophages can be
enhanced after removal of sialic acid from the cells with
neuraminidase, as observed in our lab [32]. Desialylation
Figure 2 Effect of cell density on susceptibility of CHOSn-CD163 and PK15Sn-CD163 cells to PRRSV infection. CHOSn-CD163 and PK15Sn-CD163 cells were 
cultivated for 2 days before they were inoculated with Marc-145 grown LV, Marc-145 grown VR-2332 or macrophage grown LV. The black bars repre-
sent a cell density of 100 000 cells/ml, the grey bars 200 000 cells/mL and the white bars 300 000 cells/ml. The graphs show the percentage of infected 
cells. Values represent mean ± SD of three experiments.Delrue et al. BMC Biotechnology 2010, 10:48
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of macrophages enhances sialoadhesin-mediated lectin
activity [33]. Since the interaction between sialic acids on
PRRSV and sialoadhesin is important for infection of
cells [34], desialylation of the CHOSn-CD163 and PK15Sn-
CD163 cells can probably enhance the amount of infected
cells by macrophage grown virus. Therefore, to increase
the infection rate of macrophage grown virus infection, 3
CHOSn-CD163 cell clones (IC5, ID9 and IF3) and 2 PK15Sn-
CD163 cell clones (IXH7 and IXA3) were seeded at differ-
ent densities (100 000, 200 000 or 300 000 cells/mL) and
were infected at different days post seeding (1, 2 or 3 days
p o s t  s e e d i n g )  w i t h  5 0  μ L  c o n t a i n i n g  1 0 4 TCID50 mac-
rophage grown LV, after treatment of the cells with
neuraminidase to remove cis-acting sialic acids. After 2
dpi, the cells were fixed and stained. The results showed
that treatment of the PK15Sn-CD163 cells at 200 000 cell/mL
with neuraminidase before inoculation enhanced infec-
tion of the cells with macrophage grown virus (Figure 2).
Analysis of PRRSV attachment, internalization, disassembly 
and infection of CHOSn-CD163 and PK15Sn-CD163 cells
To investigate if virus attachment, internalization, disas-
sembly and infection occurs in the CHOSn-CD163  and
PK15Sn-CD163 cells, CHOSn-CD163 clone IC5 and PK15Sn-
CD163 clone IXH7 were inoculated with Marc-145 grown
LV (moi 1), Marc-145 grown VR-2332 (moi 1) and mac-
rophage grown LV (moi 1). The virus was stained by
immunofluorescence at different stages of the viral repli-
cation cycle. First, the virus particles were clearly shown
to attach to the cells. Then, virus particles were internal-
ized into the cells, with macrophage grown virus being
less efficient than Marc-145 grown virus. After internal-
ization, the particles were uncoated to release the
genome. Finally, infection occurred (Figure 3). In general,
Marc-145 grown virus infected the cells more efficiently
than macrophage grown virus. Further, Marc-145 grown
VR-2332 infected the PK15Sn-CD163 cells more efficiently
than Marc-145 grown LV, while this was equal for the
CHOSn-CD163 cells. Infection of the cells with macrophage
grown virus was very low. Treatment of the cells with
neuraminidase before inoculation enhanced the infection
rate of PK15Sn-CD163 cells. The PK15Sn-CD163 cells were
infected most efficiently in all cases (Figure 3).
PRRSV infection kinetics on CHOSn-CD163 and PK15Sn-CD163 
cells
To investigate the susceptibility of CHOSn-CD163  and
PK15Sn-CD163 cells to PRRSV infection, cells were seeded
at 200 000 cells/mL and infected with Marc-145 grown
LV, Marc-145 grown VR-2332 or macrophage grown LV
at a moi of 0.2 at 2 days post seeding. For macrophage
grown virus infection, a comparison was made between
infection of cells treated with neuraminidase and
untreated cells. The cells were fixed 1, 2, 3, 5 and 7 dpi
and stained by immunoperoxidase. Figure 4 shows that
Marc-145 grown VR-2332 could infect more CHOSn-
CD163 cells than Marc-145 grown LV, while both strains
infect PK15Sn-CD163  cells for approximately 80%. Mac-
rophage grown virus did infect a low number of cells for
the two cell lines (Figure 4). If the CHOSn-CD163  and
PK15Sn-CD163  cells were treated with neuraminidase,
infection of the PK15Sn-CD163 cells, but not the CHOSn-
CD163 cells, with macrophage grown virus was increased
(Figure 4). At 3 and 5 dpi, the highest amount of virus
infection was achieved, with up to 20% for Marc-145
grown LV and up to 40% for Marc-145 grown VR-2332 on
CHOSn-CD163  cells and up to 80% for both Marc-145
grown strains on PK15Sn-CD163 cells. The infection rate of
cells infected with macrophage grown virus did not reach
5% in both cell lines. After treatment of the cells with
neuraminidase, infection with macrophage grown virus
increased on PK15Sn-CD163 cells. In summary, Marc-145
grown LV and Marc-145 grown VR-2332 could infect the
cell lines most efficiently. Macrophage grown virus gave
little infection, but if the cells were first treated with
neuraminidase, infection was slightly better in the case of
PK15Sn-CD163 cells.
Virus production in CHOSn-CD163 and PK15Sn-CD163 cells
To determine virus production in CHOSn-CD163  and
PK15Sn-CD163 cells, the cells were inoculated with Marc-
145 grown VR-2332, macrophage grown LV, macrophage
grown 07V063, macrophage grown 08V204 and mac-
rophage grown 08V194. When the virus was passaged for
several times, the virus titer increased, especially in
PK15Sn-CD163 cells, to reach a stable level starting from
passage 3. A titer of 106.0 ± 0.3 and 105.0 ± 0.6 TCID50/mL was
obtained after 3 passages in CHOSn-CD163 cells for VR-
2332 and 07V063 respectively. LV, 08V204 and 08V194
did not grow on CHOSn-CD163 cells. A titer of 105.1 ± 0.8,
107.4 ± 0.3, 108.0 ± 0.3, 105.8 ± 0.5 and 106.5 ± 0.3 TCID50/mL was
achieved after 3 passages in PK15Sn-CD163 cells for LV, VR-
2332, 07V063, 08V204 and 08V194 respectively. All virus
titers of virus produced in both cell lines till passage 5 are
represented in Figure 5. As a comparison, also virus yield
obtained after 3 passages in Marc-145 cells was deter-
mined via titration on macrophages, revealing a titer of
106.6 ± 0.3, 106.8 ± 0.6, 107.1 ± 0.6, 105.5 ± 0.6 and 107.1 ± 0.3
TCID50/mL for LV, VR-2332, 07V063, 08V204 and
08V194 respectively. Similar virus titers are thus pro-
duced in PK15Sn-CD163 and Marc-145 cells.
Virus sequencing after passaging virus in PK15Sn-CD163 cells
As most virus strains grow better on PK15Sn-CD163 cells,
this cell line was more interesting to grow vaccine virus
than CHOSn-CD163  cells. To produce vaccine virus forDelrue et al. BMC Biotechnology 2010, 10:48
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inactivated vaccines mutation of structural proteins
should not occur. Therefore, PK15Sn-CD163 grown virus
was sequenced and compared to the sequence of the orig-
inal virus. VR-2332 and 07V063 grown on PK15Sn-CD163
cells showed no differences after 5 passages compared to
the original virus strain. PK15Sn-CD163 grown LV showed 1
amino acid (aa), 08V194 2 aa and 08V204 3 aa differences
c o m p a r e d  t o  m a c r o p h a g e  g r o w n  v i r u s .  F o r  L V  t h e  a a
change was in ORF4 (N37D). The aa differences of
08V194 were located in ORF2 (E73D) and in ORF5
(N37S). For 08V204 the aa differences were situated in
ORF2 (N37D), ORF4 (I121V) and ORF5 (N37D).
Discussion
PRRSV replicates efficiently in ex vivo cultivated primary
macrophages, which are the natural host cells. For vac-
cine virus production however, this cell type cannot be
used, because of batch variation, risk of contamination
with other pathogens and high production costs. PRRSV
susceptible cell lines, such as the African green monkey
derived cell lines, like Marc-145, have the potential to
overcome problems associated with the use of primary
macrophages, such as up-scaling and safety. However,
PRRSV infects Marc-145 cells via a different entry path-
way compared to macrophages, which results in adapta-
tion of the virus for growth on Marc-145 cells [26].
Several non-permissive cells transfected with RNA of
PRRSV could produce infectious virus. It is therefore sug-
gested that the susceptibility of cells for PRRSV infection
is determined by membrane-associated components [35].
In a previous study, it was shown that non-permissive
cells transiently transfected with Sn only sustained inter-
nalization, but not infection [19]. Non-permissive cells
transiently transfected with CD163 may allow a low level
of infection depending on the cell type used [24]. Van
Gorp et al. showed that co-expression of both Sn and
scavenger receptor CD163 are needed for an efficient
PRRSV infection [20]. A virus titer ranging between 102.4
and 105.5 TCID50/ m L  c o u l d  b e  o b t a i n e d  u p o n  P R R S V
infection of cells transiently transfected with recombi-
nant Sn and CD163 [20]. Since only a part of the cells
were transfected upon transient transfection, it was
expected that the virus titer would be higher if stably
transfected cell lines could be used. In this study, cell lines
that express both recombinant Sn and CD163 (CHOSn-
CD163 and PK15Sn-CD163) were made, as both receptors are
involved in infection of the natural host cell, the mac-
rophage [20,27]. The constructed CHOSn-CD163  and
PK15Sn-CD163 cell lines were first analyzed for their PRRSV
susceptibility. They were both susceptible for PRRSV,
because LV and VR-2332 virus attachment, internaliza-
tion, disassembly and infection occurred in both cell
lines.
When analyzing the PRRSV susceptibility, it was shown
that primary infection of the cell lines was more efficient
with Marc-145 grown virus than macrophage grown
Figure 3 Attachment, internalization, disassembly and infection in CHOSn-CD163 and PK15Sn-CD163 cells. CHOSn-CD163 clone IC5 and PK15Sn-CD163 
clone IXH7 were inoculated with Marc-145 grown LV, Marc-145 grown VR-2332 or macrophage grown LV. The different stages of the viral replication 
cycle were investigated by immunofluorescence staining of the virus.Delrue et al. BMC Biotechnology 2010, 10:48
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virus. The infection rate of macrophage grown virus was
very low, most likely because binding and internalization
of macrophage grown virus particles into the cell lines
was not efficient. The interaction of macrophage grown
PRRSV with Sn, the receptor mediating binding to and
internalization into the cells, is probably not efficient.
This can be due to sialic acids present on the cells inter-
fering with Sn, resulting in competition with sialic acid on
PRRSV. This hypothesis is based on the observation that
CD33, also a member of the sialoadhesin family, trans-
fected in COS cells were not able to bind to red blood
cells, containing sialic acid, unless the COS cells were first
treated with sialidase to remove endogenous ligands
[36,37]. Also CHOSn cells showed no binding of red blood
cells unless they were treated with neuraminidase [32].
To investigate if neuraminidase could improve mac-
rophage grown PRRSV infection, the CHOSn-CD163 and
PK15Sn-CD163 cells were first treated with Vibrio cholerae
neuraminidase (Roche) to remove potential cis-acting
sialic acids that could interfere with the sialic acid binding
capacity of Sn [32]. This resulted in an increased amount
of macrophage grown virus infected cells. These results
suggest that the low virus titers are related with a low
binding capacity of PRRSV to Sn, because of sialic acid
present on the CHOSn-CD163 and PK15Sn-CD163 cells. Marc-
145 grown PRRSV will most likely also contain sialic
acids that can interfere with Sn. Our hypothesis is that
also the production of Marc-145 grown virus can be
improved by neuraminidase treatment of the cells and
needs to be further investigated.
However, using an expensive product like Vibrio chol-
erae neuraminidase is not ideal for vaccine production.
To avoid this problem, virus is grown via several passages
on the cell lines. Normally, titers of 105-107 TCID50/mL
can be obtained on Marc-145 cells after 5 to 7 passages
[16,38]. The results show that the PK15Sn-CD163 cells give
similar results as a recent macrophage cell line trans-
fected with CD163 [39]. In addition, the PK15Sn-CD163
cells also express Sn, which is important to facilitate virus
entry. The macrophage cell line transfected with CD163
Figure 4 PRRSV infection kinetics in CHOSn-CD163 and PK15Sn-CD163 cells. CHOSn-CD163 and PK15Sn-CD163 cells were inoculated with Marc-145 grown 
LV (open square), Marc-145 grown VR-2332 (black square) or macrophage grown LV (black circle). After 1, 2, 3, 5 and 7 dpi the cells were fixed and an 
immunoperoxidase staining was performed. The amount of infected cells were counted and expressed in the graphs as the percentage of infected 
cells. Values represent mean ± SD of three experiments.Delrue et al. BMC Biotechnology 2010, 10:48
http://www.biomedcentral.com/1472-6750/10/48
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Figure 5 Virus production on CHOSn-CD163 and PK15Sn-CD163 cells. CHOSn-CD163 clone IC5 and PK15Sn-CD163 clone IXH7 were inoculated with Marc-
145 grown VR-2332 (black square), macrophage grown LV (open circle), macrophage grown 07V063 (black triangle), macrophage grown 08V204 
(open triangle) or macrophage grown 08V194 (black diamond). The virus was passages 5 times and the supernatant was titrated. Values represent 
mean ± SD of three titrations.Delrue et al. BMC Biotechnology 2010, 10:48
http://www.biomedcentral.com/1472-6750/10/48
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also expresses Sn [39], which confirms that both recep-
tors, Sn and CD163, are important for an efficient virus
production. Virus growth on PK15Sn-CD163 cells resulted
in higher titers than growth on CHOSn-CD163 cells and the
virus titer achieved on PK15Sn-CD163 cells was equal to the
titer on Marc-145 cells, which makes the PK15Sn-CD163 cell
line an interesting tool for virus production.
It is reported that due to adaptation of PRRSV to Marc-
145 cells, mutations in non-structural, but also structural
viral proteins may occur [40-42]. For the production of an
inactivated virus vaccine, mutations in ORFs encoding
viral structural proteins are not desired, since this can
influence the induction of a virus neutralizing antibody
response. The virus grown on PK15Sn-CD163  cells is
expected to show less mutations than after growth on
Marc-145 cells, since the PK15Sn-CD163 cells express Sn
and CD163, two receptors important in the entry of the
virus in macrophages and the entry-associated domains
are probably involved in the induction of a neutralizing
antibody response. To investigate if virus grown on
PK15Sn-CD163 c e l l s  s h o w e d  m u t a t i o n  i n  O R F s  e n c o d i n g
viral structural proteins, ORF2a, 3, 4, 5, 6 and 7 were
sequenced. 07V063 and VR-2332 grown on PK15Sn-CD163
cells showed a 100% aa identity with 07V063 grown on
macrophages and VR-2332 grown on Marc-145 cells. LV
grown on PK15Sn-CD163 cells had 1 aa changed in ORF 4
compared to macrophage grown LV, which resulted in a
loss of a putative glycosylation site. The mutation, how-
ever, was not situated in a known neutralizing epitope
[43,44]. PK15Sn-CD163 grown 08V194 had 2 aa difference
compared to macrophage grown 08V194. There was 1 aa
changed in ORF5. This resulted not in a loss of a glycosy-
lation site, but the glycosylation site moved to another
place. The mutation was not situated in a known neutral-
izing epitope [45]. The second aa change was located in
ORF2a, however a change from E to D is supposed to
have no effect on the protein structure since those aa are
similar. For 08V204 grown on PK15Sn-CD163 cells, there
was 1 aa changed in ORF2a, 1 aa in ORF4 and 1 aa in
ORF5. The mutation in ORF4, however was a change
from I to V, which are comparable aa and will not have an
influence on the protein structure. The mutation in ORF5
results in a loss of a putative glycosylation site, but is not
located in a known neutralizing epitope [45]. The muta-
tion in ORF5 of 08V194 and 08V204 are both on position
37. This position varies among different PRRSV strains
and is a not well conserved glycosylation site [46]. These
results indicate that the PK15Sn-CD163 cells are useful for
production of vaccine virus, but each strain should be
investigated for aa changes in the structural proteins
before use in inactivated vaccine production. Experi-
ments are ongoing to test the immunogenicity of inacti-
vated PRRSV grown on PK15Sn-CD163 cells and the effect
of the minor aa changes on the induction of a protective
immunity towards challenge virus.
The observation that all tested strains grow well on the
PK15Sn-CD163 cells also suggests that these cells might be
useful for virus isolation. Currently Marc-145 cells are
used for diagnostics, but it has been shown that not all
PRRSV strains can be detected on those cells [47]. Mac-
rophages, the natural host cell of PRRSV, are more effi-
cient for virus isolation [47]. The difference in isolation
efficiency between Marc-145 cells and macrophages is
suggesting that another receptor next to CD163 is
involved in infection as Marc-145 cells and macrophages
both express CD163 [20,24]. The PK15Sn-CD163 cells can
be useful for virus isolation, because of the expression of
both CD163 and Sn, but needs to be further investigated.
Conclusions
A PRRSV susceptible cell line expressing two major
receptors for infection in macrophages, namely Sn and
CD163, was constructed. It is shown that virus produc-
tion from genotype 1 (LV, 3 Belgian strains) and genotype
2 (VR-2332) on the cell line is possible with virus titers
being equal to the virus titers achieved on Marc-145 cells.
No or only a few mutations occur in the ORFs encoding
viral structural proteins and the mutations that occur for
some viruses are not situated in known neutralizing
epitopes. Therefore it is assumed that an inactivated
PRRSV vaccine based on virus grown on the PK15Sn-CD163
cells will be able to induce a proper immune response,
but this is currently under investigation. In addition, the
PK15Sn-CD163 cells can probably also be used for virus iso-
lation, because of the expression of both Sn and CD163,
but this also needs to be confirmed.
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